ClinicalTrials.Veeva

Menu
O

Optimal Clinical Trials Ltd | Auckland, New Zealand

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

BI 456906
BTX 1204
Ocrelizumab
KAN-101
Filgotinib
ZGN-1061
Bimagrumab
Survodutide
RBN-3143
Q-122

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 33 total trials

A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis (Ocarina II)

This study will evaluate the pharmacokinetics, pharmacodynamics, safety, immunogenicity, and radiological and clinical effects of subcutaneous (SC) a...

Active, not recruiting
Primary Progressive Multiple Sclerosis
Relapsing Multiple Sclerosis
Drug: Ocrelizumab SC
Drug: Dexamethasone given orally

This study is to evaluate the Pharmacodynamic (PD), safety, tolerability, Pharmacokinetic (PK), and plasma biomarker response of KAN-101 in participa...

Enrolling
Celiac Disease
Drug: Cohort 2 in Part A
Drug: Group 4 in Part B and Part C

This is a Phase 2 pilot study to examine the preliminary efficacy, safety and PK of TAVO101 in adult patients with moderate and severe AD.

Enrolling
Atopic Dermatitis
Drug: TAVO101

The purpose of this study is to demonstrate the efficacy of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) compared to placeb...

Enrolling
Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
Biological: ExPEC9V
Other: Placebo

The main purpose of Part A of this study is to evaluate the safety and tolerability of mRNA-1345 vaccine and to demonstrate the efficacy of a single...

Active, not recruiting
Respiratory Syncytial Virus
Drug: Placebo
Drug: mRNA-1345

This study is open to adults who are at least 18 years old and have a body mass index (BMI)bof 27 kg/m2 or more. People can take part if they have ca...

Enrolling
Obesity
Drug: Placebo
Drug: survodutide

A study of sevasemten (EDG-5506) in Becker muscular dystrophy (known as CANYON) and pivotal cohort (known as GRAND CANYON). The EDG-5506-201 CANYON s...

Enrolling
Becker Muscular Dystrophy
Drug: Placebo
Drug: Sevasemten 10 mg

RBN-3143 Background: PARP proteins are members of a family of seventeen ADP-ribosyltransferase (ART) enzymes that regulate cellular processes includi...

Enrolling
Atopic Dermatitis
Drug: RBN-3143

A phase 2 study to assess the efficacy of bimagrumab alone or in addition to semaglutide to assess efficacy and safety in overweight or obese men and...

Active, not recruiting
Overweight or Obesity
Obese
Drug: Semaglutide
Biological: Bimagrumab

This is a phase 3, randomized, double-blind, active comparator-controlled study of the safety, tolerability, and immunogenicity of V116 in pneumococc...

Active, not recruiting
Pneumococcal Disease
Biological: V116
Biological: PPSV23

The aim of this randomised, double-blind, placebo controlled clinical food trial is to determine if the medical food SBD121 Synbiotic (prebiotic and...

Enrolling
Rheumatoid Arthritis
Other: Placebo
Other: SBD121

Trial sponsors

Pfizer logo
Boehringer Ingelheim logo
Merck Sharp & Dohme (MSD) logo
AbbVie logo
Akeso logo
Becton, Dickinson and Company (BD) logo
B
B
C
Edgewise Therapeutics logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems